Display options
Cite
Peleman C, Camilleri M. Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. Clin Transl Gastroenterol. 2016;7(10):e195doi: 10.1038/ctg.2016.52.
Peleman, C., & Camilleri, M. (2016). Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. Clinical and translational gastroenterology, 7(10), e195. https://doi.org/10.1038/ctg.2016.52
Peleman, Cedric, and Camilleri, Michael. "Rifaximin, Microbiota Biology, and Hepatic Encephalopathy." Clinical and translational gastroenterology vol. 7,10 (2016): e195. doi: https://doi.org/10.1038/ctg.2016.52
Peleman C, Camilleri M. Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. Clin Transl Gastroenterol. 2016 Oct 06;7(10):e195. doi: 10.1038/ctg.2016.52. PMID: 27711069; PMCID: PMC5288587.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Gastroenterol. 2016 Oct 06;7(10):e195. doi: 10.1038/ctg.2016.52.

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy.

Clinical and translational gastroenterology

Cedric Peleman, Michael Camilleri

Affiliations

  1. Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA.

PMID: 27711069 PMCID: PMC5288587 DOI: 10.1038/ctg.2016.52

Abstract

Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact on the composition of microbiota, rifaximin altered bacterial functions, ameliorated local and systemic inflammation, and reduced enterocyte glutaminase activity. We discuss these effects as well as the interpretation of the permeability studies, given the potential interaction of dysbiosis with dysfunctional intestinal barrier, leading to systemic inflammation and increased uptake of bacterial metabolites that contribute to MHE in the presence of hepatic dysfunction.

Conflict of interest statement

Guarantor of the article: Michael Camilleri, MD. Specific author contributions: Both authors performed the literature review, and drafting and revision of the manuscript. Financial support: M.C. is fu

References

  1. J Antimicrob Chemother. 2010 Dec;65(12):2556-65 - PubMed
  2. PLoS One. 2013;8(4):e60042 - PubMed
  3. Clin Exp Gastroenterol. 2015 Dec 04;8:309-25 - PubMed
  4. J Hepatol. 2014 May;60(5):940-7 - PubMed
  5. J Chemother. 2016 Jun 10;:1-7 - PubMed
  6. Clin Transl Gastroenterol. 2016 May 26;7:e173 - PubMed
  7. Eur J Pharm Sci. 2014 May 13;55:12-9 - PubMed
  8. Eur J Pharmacol. 2011 Oct 1;668(1-2):317-24 - PubMed
  9. Clin Transl Gastroenterol. 2016 Aug 25;7(8):e187 - PubMed
  10. Gastroenterology. 2012 May;142(5):1100-1101.e2 - PubMed
  11. J Steroid Biochem Mol Biol. 2016 Jun;160:94-7 - PubMed
  12. Antimicrob Agents Chemother. 2010 Sep;54(9):3618-24 - PubMed
  13. Am J Physiol Gastrointest Liver Physiol. 2012 Oct;303(7):G775-85 - PubMed
  14. Mayo Clin Proc. 2015 Aug;90(8):1116-24 - PubMed

Publication Types

Grant support